Nothing Special   »   [go: up one dir, main page]

Chew et al., 2024 - Google Patents

Secreted dengue virus NS1 from infection is predominantly dimeric and in complex with high-density lipoprotein

Chew et al., 2024

View HTML
Document ID
6568483842026051523
Author
Chew B
Ngoh A
Phoo W
Chan K
Ser Z
Tulsian N
Lim S
Weng M
Watanabe S
Choy M
Low J
Ooi E
Ruedl C
Sobota R
Vasudevan S
Luo D
Publication year
Publication venue
Elife

External Links

Snippet

Severe dengue infections are characterized by endothelial dysfunction shown to be associated with the secreted nonstructural protein 1 (sNS1), making it an attractive vaccine antigen and biotherapeutic target. To uncover the biologically relevant structure of sNS1, we …
Continue reading at elifesciences.org (HTML) (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G01N33/576—Immunoassay; Biospecific binding assay for hepatitis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Similar Documents

Publication Publication Date Title
Yang et al. A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity
Saunders et al. Neutralizing antibody vaccine for pandemic and pre-emergent coronaviruses
Li et al. The development of a recombinant hepatitis E vaccine HEV 239
Chew et al. Secreted dengue virus NS1 from infection is predominantly dimeric and in complex with high-density lipoprotein
Ribeiro-Filho et al. Cryo-EM structure of the mature and infective Mayaro virus at 4.4 Å resolution reveals features of arthritogenic alphaviruses
Brouwer et al. Lassa virus glycoprotein nanoparticles elicit neutralizing antibody responses and protection
WO2015139784A1 (en) Distinguishing flavivirus infection using a recombinant mutant envelope protein
Fan et al. Beta-propiolactone inactivation of coxsackievirus A16 induces structural alteration and surface modification of viral capsids
CN103476788A (en) Immunogenic chikungunya virus peptides
Das et al. Molecular and structural insights into the life cycle of rubella virus
Davenport et al. Phage-like particle vaccines are highly immunogenic and protect against pathogenic coronavirus infection and disease
Bereszczak et al. Assessment of differences in the conformational flexibility of hepatitis B virus core‐antigen and e‐antigen by hydrogen deuterium exchange‐mass spectrometry
Chen et al. Japanese encephalitis virus–primed CD8+ T cells prevent antibody-dependent enhancement of Zika virus pathogenesis
US9718862B2 (en) Polypeptides and their use in treating and limiting respiratory syncytial virus infection
Isaacs et al. Structure and antigenicity of divergent Henipavirus fusion glycoproteins
Modjarrad et al. Preclinical characterization of the Omicron XBB. 1.5-adapted BNT162b2 COVID-19 vaccine
Georgiev et al. Resurfaced ZIKV EDIII nanoparticle immunogens elicit neutralizing and protective responses in vivo
US9701720B2 (en) Epitope-scaffold immunogens against respiratory syncytial virus (RSV)
Wang et al. Structure, immunogenicity, and protective mechanism of an engineered enterovirus 71-like particle vaccine mimicking 80S empty capsid
AU2011334543B2 (en) Compositions and methods
Liang et al. Structure and computation-guided design of a mutation-integrated trimeric RBD candidate vaccine with broad neutralization against SARS-CoV-2
Trauchessec et al. Complementary use of mass spectrometry and cryo-electron microscopy to assess the maturity of live attenuated dengue vaccine viruses
Long et al. Recombinant VLPs empower RBM peptides showing no immunogenicity in native SARS-COV-2 protein to elicit a robust neutralizing antibody response
WO2023104154A1 (en) Antigenic polypeptide and use thereof
EP4168426A1 (en) Fatty acid complexes of coronavirus spike protein and their use